Jun Sugisaka

1.1k total citations
20 papers, 680 citations indexed

About

Jun Sugisaka is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Jun Sugisaka has authored 20 papers receiving a total of 680 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in Jun Sugisaka's work include Cancer Immunotherapy and Biomarkers (12 papers), Lung Cancer Treatments and Mutations (9 papers) and Lung Cancer Research Studies (4 papers). Jun Sugisaka is often cited by papers focused on Cancer Immunotherapy and Biomarkers (12 papers), Lung Cancer Treatments and Mutations (9 papers) and Lung Cancer Research Studies (4 papers). Jun Sugisaka collaborates with scholars based in Japan, Italy and United States. Jun Sugisaka's co-authors include Yukihiro Toi, Shunichi Sugawara, Kyoji Tsurumi, Hisashi Shimizu, Tomoiki Aiba, Yutaka Domeki, Shinsuke Yamanda, Keisuke Terayama, Yuichiro Kimura and Yosuke Kawashima and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Annals of Oncology.

In The Last Decade

Jun Sugisaka

18 papers receiving 677 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jun Sugisaka Japan	8	602	287	109	82	52	20	680
Audrey Simonaggio France	10	445 0.7×	278 1.0×	82 0.8×	104 1.3×	32 0.6×	23	567
Sachiko Kawana Japan	7	503 0.8×	249 0.9×	115 1.1×	37 0.5×	49 0.9×	17	590
Noelia Vilariño Spain	12	417 0.7×	323 1.1×	74 0.7×	98 1.2×	65 1.3×	29	593
Mary Kate Kasler United States	6	620 1.0×	191 0.7×	172 1.6×	76 0.9×	48 0.9×	8	713
Raphael Brandão Moreira United States	11	504 0.8×	369 1.3×	116 1.1×	106 1.3×	50 1.0×	30	719
J.M. Sánchez-Torres Spain	13	614 1.0×	428 1.5×	99 0.9×	150 1.8×	42 0.8×	21	772
Tomoiki Aiba Japan	7	496 0.8×	235 0.8×	107 1.0×	31 0.4×	49 0.9×	18	544
Beung‐Chul Ahn South Korea	12	497 0.8×	366 1.3×	106 1.0×	106 1.3×	17 0.3×	38	621
Kyoji Tsurumi Japan	6	492 0.8×	232 0.8×	103 0.9×	28 0.3×	47 0.9×	11	531
Keisuke Terayama Japan	6	491 0.8×	230 0.8×	103 0.9×	28 0.3×	47 0.9×	10	531

Countries citing papers authored by Jun Sugisaka

Since Specialization

Citations

This map shows the geographic impact of Jun Sugisaka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jun Sugisaka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jun Sugisaka more than expected).

Fields of papers citing papers by Jun Sugisaka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jun Sugisaka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jun Sugisaka. The network helps show where Jun Sugisaka may publish in the future.

Co-authorship network of co-authors of Jun Sugisaka

This figure shows the co-authorship network connecting the top 25 collaborators of Jun Sugisaka. A scholar is included among the top collaborators of Jun Sugisaka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jun Sugisaka. Jun Sugisaka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Abe, Masahiko, Kenta Murotani, Yuki Sato, et al.. (2025). A multicenter, randomized, controlled, open-label trial to determine the optimal duration of steroid therapy for mild pneumonitis associated with immune checkpoint inhibitors.. Journal of Clinical Oncology. 43(16_suppl). 12006–12006. 1 indexed citations

Kawashima, Yosuke, Yasuhiko Munakata, Yusuke Yamazaki, et al.. (2024). Successful Application of Tocilizumab in a Patient With Neoadjuvant Immunochemotherapy‐Induced Cytokine Release Syndrome. Cancer Reports. 7(7). e2145–e2145.

Murakami, Yosuke, Yosuke Kawashima, Yusuke Yamazaki, et al.. (2024). Successful application of lorlatinib in a 23‐year‐old patient with anaplastic lymphoma kinase (ALK)‐positive lung cancer and multiple brain metastases. Cancer Reports. 7(2). e1981–e1981.

Horinouchi, Hidehito, Isao Yokota, Teppei Yamaguchi, et al.. (2024). Durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non–small‐cell lung cancer (NEJ056). Cancer Science. 115(11). 3705–3717. 1 indexed citations

Shibaki, Ryota, Akira Sano, Yuka Kitamura, et al.. (2024). Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancer. Journal for ImmunoTherapy of Cancer. 12(2). e007987–e007987. 8 indexed citations

Sugisaka, Jun, Yukihiro Toi, Yosuke Kawashima, et al.. (2023). Efficacy of paclitaxel‐carboplatin with bevacizumab as a late‐line therapy for patients with advanced nonsquamous non‐small cell lung cancer: A platinum rechallenge. Thoracic Cancer. 14(31). 3140–3146. 1 indexed citations

Tsukita, Yoko, Takehiro Tozuka, Shinobu Hosokawa, et al.. (2023). First-line immune checkpoint inhibitors alone or in combination with chemotherapy in real-life elderly patients with advanced non-small cell lung cancer (NEJ057).. Journal of Clinical Oncology. 41(16_suppl). 9012–9012. 7 indexed citations

Aiba, Tomoiki, Jun Sugisaka, Hisashi Shimizu, et al.. (2021). Gene expression signatures as candidate biomarkers of response to PD-1 blockade in non-small cell lung cancers. PLoS ONE. 16(11). e0260500–e0260500. 6 indexed citations

Hotta, T, Yukari Tsubata, Kosuke Hamai, et al.. (2020). Pharmacokinetics of edoxaban in EGFR-mutated non-small cell lung cancer patients with venous thromboembolism. Respiratory Investigation. 59(3). 327–334. 4 indexed citations

10.

Naqash, Abdul Rafeh, Biagio Ricciuti, Dwight H. Owen, et al.. (2020). Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort. Cancer Immunology Immunotherapy. 69(7). 1177–1187. 72 indexed citations

11.

Toi, Yukihiro, Yuichiro Kimura, Yutaka Domeki, et al.. (2019). Association of low body surface area with dose reduction and/or discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis: a pilot study.. PubMed Central. 36(1). 74–78. 6 indexed citations

12.

Toi, Yukihiro, Shunichi Sugawara, Mari Aso, et al.. (2019). P1.16-29 Profiling Immune-Related Adverse Events (irAEs) in Patients with Anti-PD-1 for Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(10). S598–S599. 1 indexed citations

13.

Aso, Mari, Yukihiro Toi, Jun Sugisaka, et al.. (2019). Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer. The Oncologist. 25(3). e536–e544. 46 indexed citations

14.

Sugisaka, Jun, Yukihiro Toi, Masataka Taguri, et al.. (2019). Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab. JMA Journal. 3(1). 58–66. 22 indexed citations

15.

Sugisaka, Jun, Shunichi Sugawara, Yukihiro Toi, et al.. (2019). Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world. Annals of Oncology. 30. ix112–ix113. 2 indexed citations

16.

Toi, Yukihiro, Shunichi Sugawara, Jun Sugisaka, et al.. (2018). Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer. JAMA Oncology. 5(3). 376–376. 249 indexed citations

17.

Toi, Yukihiro, Shunichi Sugawara, Yosuke Kawashima, et al.. (2018). Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab. The Oncologist. 23(11). 1358–1365. 195 indexed citations

18.

Toi, Yukihiro, Shunichi Sugawara, Yosuke Kawashima, et al.. (2017). P2.07-004 Immune-Related Adverse Events (irAEs) of Nivolumab Predicts Clinical Benefit in Advanced Lung Cancer Patients. Journal of Thoracic Oncology. 12(11). S2417–S2417. 1 indexed citations

19.

Idogawa, Masashi, et al.. (2014). Array-based genome-wide RNAi screening to identify shRNAs that enhance p53-related apoptosis in human cancer cells. Oncotarget. 5(17). 7540–7548. 7 indexed citations

20.

Sasaki, Yasushi, Ryota Koyama, Reo Maruyama, et al.. (2012). CLCA2, a target of the p53 family, negatively regulates cancer cell migration and invasion. Cancer Biology & Therapy. 13(14). 1512–1521. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact